Nornir Labs
Nornir Labs develops a platform-agnostic ultraphenotypic antimicrobial susceptibility testing (AST) platform that delivers ultrafast results across diverse laboratory settings. The technology decouples the assay from specific hardware, enabling clinical microbiology labs to integrate rapid susceptibility data into existing workflows without costly equipment replacements. The company is currently in stealth mode.
- Healthcare Technology
- Biotechnology
Funding
Founders
Founder details are not available yet.
Product
Problem
Traditional antimicrobial susceptibility testing (AST) is slow and often platform-specific, delaying targeted antibiotic therapy and contributing to the rise of antimicrobial resistance. Clinicians lack rapid, actionable diagnostic data that works across diverse laboratory settings, hindering effective treatment decisions and patient outcomes.
Solution
Nornir Labs develops an ultraphenotypic AST platform that is agnostic to the underlying testing technology, enabling rapid and consistent susceptibility results across different laboratory infrastructures. The solution delivers ultrafast diagnostic turnaround, allowing clinicians to adjust antimicrobial therapy earlier in the treatment pathway. By decoupling the assay from specific hardware, Nornir Labs makes advanced susceptibility testing accessible to a broader range of diagnostic environments without requiring costly platform replacements. The versatile workflow integrates easily into existing clinical microbiology operations to directly support better patient management and stewardship of antimicrobial resources.
Target Audience
Primary customers are clinical microbiology laboratories and hospital diagnostic centers that perform antimicrobial susceptibility testing and need rapid results to guide treatment for patients with bacterial infections.
Features
- Platform-agnostic design that runs the same ultraphenotypic assay on multiple existing AST instrument types
- Ultrafast time-to-result, significantly compressing the diagnostic window compared to conventional phenotypic methods
- Ultraphenotypic analysis capturing a rich, functional profile of the pathogen's resistance beyond traditional categorical readings
- Versatile testing workflow engineered for straightforward adoption across heterogeneous clinical laboratory environments